Literature DB >> 23943670

Adalimumab: Another Treatment Option for Moderate-to-Severe UC.

Asher A Kornbluth1.   

Abstract

Entities:  

Year:  2013        PMID: 23943670      PMCID: PMC3740811     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


× No keyword cloud information.
  4 in total

1.  Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.

Authors:  William J Sandborn; Gert van Assche; Walter Reinisch; Jean-Frederic Colombel; Geert D'Haens; Douglas C Wolf; Martina Kron; Mary Beth Tighe; Andreas Lazar; Roopal B Thakkar
Journal:  Gastroenterology       Date:  2011-11-04       Impact factor: 22.682

2.  Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease.

Authors:  R Panaccione; J-F Colombel; W J Sandborn; P Rutgeerts; G R D'Haens; A M Robinson; J Chao; P M Mulani; P F Pollack
Journal:  Aliment Pharmacol Ther       Date:  2010-03-18       Impact factor: 8.171

3.  Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.

Authors:  Walter Reinisch; William J Sandborn; Daniel W Hommes; Geert D'Haens; Stephen Hanauer; Stefan Schreiber; Remo Panaccione; Richard N Fedorak; Mary Beth Tighe; Bidan Huang; Wendy Kampman; Andreas Lazar; Roopal Thakkar
Journal:  Gut       Date:  2011-01-05       Impact factor: 23.059

4.  Infliximab for induction and maintenance therapy for ulcerative colitis.

Authors:  Paul Rutgeerts; William J Sandborn; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Suzanne Travers; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.